Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice

Journal of Veterinary Pharmacology and Therapeutics

Volumn 32, Issue 1, 2009, Pages 87-96

  Geyer, J ^a   Gavrilova, O ^a   Petzinger, E ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GLYCOPROTEIN P; IVERMECTIN; MULTIDRUG RESISTANCE PROTEIN 1; SELAMECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PENETRATION; GENE; GENE MUTATION; KIDNEY; KNOCKOUT MOUSE; LIVER; MAXIMUM PLASMA CONCENTRATION; MDR1 GENE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TESTIS; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTIPARASITIC AGENTS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; INJECTIONS, INTRAVENOUS; IVERMECTIN; MALE; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGAN SPECIFICITY; P-GLYCOPROTEINS; RANDOM ALLOCATION; SAFETY; TISSUE DISTRIBUTION;

CANIS FAMILIARIS; MUS;

EID: 58449137106     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2008.01007.x     Document Type: Article

References (44)

1. Banks, B.J., Bishop, B.F., Evans, N.A., Gibson, S.P., Goudie, A.C., Gration, K.A., Pacey, M.S., Perry, D.A. Witty, M.J. (2000) Avermectins and flea control: structure-activity relationships and the selection of selamectin for development as an endectocide for companion animals. Bioorganic & Medicinal Chemistry, 8, 2017 2025.
2. Bishop, B.F., Bruce, C.I., Evans, N.A., Goudie, A.C., Gration, K.A., Gibson, S.P., Pacey, M.S., Perry, D.A., Walshe, N.D. Witty, M.J. (2000) Selamectin: a novel broad-spectrum endectocide for dogs and cats. Veterinary Parasitology, 91, 163 176.
3. Brayden, D.J. Griffin, J 2008) Ivermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers. Veterinary Research Communications, 32, 93 106.
4. Cisternino, S., Mercier, C., Bourasset, F., Roux, F. Scherrmann, J.M. (2004) Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Research, 64, 3296 3301.
5. Cooray, H.C., Blackmore, C.G., Maskell, L. Barrand, M.A. (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport, 13, 2059 2063.
6. A receptor. The Journal of Pharmacology and Experimental Therapeutics, 295, 1051 1060.
7. Dean, M., Rzhetsky, A. Allikmets, R. (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Research, 11, 1156 1166.
8. Doran, A., Obach, R.S., Smith, B.J., Hosea, N.A., Becker, S., Callegari, E., Chen, C., Chen, X., Choo, E., Cianfrogna, J., Cox, L.M., Gibbs, J.P., Gibbs, M.A., Hatch, H., Hop, C.E., Kasman, I.N., Laperle, J., Liu, J., Liu, X., Logman, M., Maclin, D., Nedza, F.M., Nelson, F., Olson, E., Rahematpura, S., Raunig, D., Rogers, S., Schmidt, K., Spracklin, D.K., Szewc, M., Troutman, M., Tseng, E., Tu, M., Van Deusen, J.W., Venkatakrishnan, K., Walens, G., Wang, E.Q., Wong, D., Yasgar, A.S. Zhang, C. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metabolism and Disposition, 33, 165 174.
9. Fassler, P.E., Tranquilli, W.J., Paul, A.J., Soll, M.D., DiPietro, J.A. Todd, K.S. (1991) Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin-sensitive Collies. Journal of the American Veterinary Medical Association, 199, 457 460.
10. Fromm, M.F. (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. International Journal of Clinical Pharmacology and Therapeutics, 38, 69 74.
11. Geyer, J., Döring, B., Godoy, J.R., Leidolf, R., Moritz, A. Petzinger, E. (2005a) Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. Journal of Veterinary Pharmacology and Therapeutics, 28, 545 551.
12. Geyer, J., Döring, B., Godoy, J.R., Moritz, A. Petzinger, E. (2005b) Development of a PCR-based diagnostic test detecting a nt230(del4) MDR1 mutation in dogs: verification in a moxidectin-sensitive Australian Shepherd. Journal of Veterinary Pharmacology and Therapeutics, 28, 95 99.
13. Geyer, J., Klintzsch, S., Meerkamp, K., Wöhlke, A., Distl, O., Moritz, A. Petzinger, E. (2007) Detection of the nt230(del4) MDR1 mutation in White Swiss Shepherd dogs: case reports of doramectin toxicosis, breed predisposition, and microsatellite analysis. Journal of Veterinary Pharmacology and Therapeutics, 30, 482 485.
14. Griffin, J., Fletcher, N., Clemence, R., Blanchflower, S. Brayden, D.J. (2005) Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. Journal of Veterinary Pharmacology and Therapeutics, 28, 257 265.
15. Hopper, K., Aldrich, J. Haskins, S.C. (2002) Ivermectin toxicity in 17 collies. Journal of Veterinary Internal Medicine, 16, 89 94.
16. Hori, S., Ohtsuki, S., Tachikawa, M., Kimura, N., Kondo, T., Watanabe, M., Nakashima, E. Terasaki, T. (2004) Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). Journal of Neurochemistry, 90, 526 536.
17. 1a binds to high- and low-affinity sites with dual effects on the γ-aminobutyric acid-gated chloride channel of cultured cerebellar granule neurons. Journal of Pharmacology and Experimental Therapeutics, 281, 261 266.
18. Ito, K., Suzuki, H., Horie, T. Sugiyama, Y. (2005) Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharmaceutical Research, 22, 1559 1577.
19. Juliano, R.L. Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta, 455, 152 162.
20. Lee, Y.J., Kusuhara, H., Jonker, J.W., Schinkel, A.H. Sugiyama, Y. (2005) Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. The Journal of Pharmacology and Experimental Therapeutics, 312, 44 52.
21. Leslie, E.M., Deeley, R.G. Cole, S.P. (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicology and Applied Pharmacology, 204, 216 237.
22. Lespine, A., Martin, S., Dupuy, J., Roulet, A., Pineau, T., Orlowski, S. Alvinerie, M. (2007) Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. European Journal of Pharmaceutical Sciences, 30, 84 94.
23. Livak, K.J. Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif.), 25, 402 408.
24. Mealey, K.L., Bentjen, S.A., Gay, J.M. Cantor, G.H. (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics, 11, 727 733.
25. Michael, B., Meinke, P.T. Shoop, W. (2001) Comparison of ivermectin, doramectin, selamectin, and eleven intermediates in a nematode larval development assay. The Journal of Parasitology, 87, 692 696.
26. Neff, M.W., Robertson, K.R., Wong, A.K., Safra, N., Broman, K.W., Slatkin, M., Mealey, K.L. Pedersen, N.C. (2004) Breed distribution and history of canine mdr1-1δ, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proceedings of the National Academy of Sciences of the United States of America, 101, 11725 11730.
27. Nies, A.T., Jedlitschky, G., König, J., Herold-Mende, C., Steiner, H.H., Schmitt, H.P. Keppler, D. (2004) Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience, 129, 349 360.
28. Novotny, M.J., Krautmann, M.J., Ehrhart, J.C., Godin, C.S., Evans, E.I., McCall, J.W., Sun, F., Rowan, T.G. Jernigan, A.D. (2000) Safety of selamectin in dogs. Veterinary Parasitology, 91, 377 391.
29. Paul, A.J., Tranquilli, W.J., Seward, R.L., Todd, K.S. Jr. DiPietro, J.A. (1987) Clinical observations in collies given ivermectin orally. American Journal of Veterinary Research, 48, 684 685.
30. Paul, A.J., Tranquilli, W.J. Hutchens, D.E. (2000) Safety of moxidectin in avermectin-sensitive collies. American Journal of Veterinary Research, 61, 482 483.
31. Paul, A.J., Hutchens, D.E., Firkins, L.D. Borgstrom, M. (2004a) Dermal safety study with imidacloprid/moxidectin topical solution in the ivermectin-sensitive collie. Veterinary Parasitology, 121, 285 291.
32. Paul, A.J., Hutchens, D.E., Firkins, L.D. Keehan, C.M. (2004b) Effects of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies. American Journal of Veterinary Research, 65, 277 278.
33. Pulliam, J.D. Preston, J.M 1989) Safety of ivermectin in target animals. In Ivermectin and Abamectin. Ed Campbell, W.C., pp. 149 161. Springer-Verlag, New York, Berlin, Heidelberg.
34. Pulliam, J.D., Seward, R.L., Henry, R.T. Steinberg, S.A. (1985) Investigating ivermectin toxicity in Collies. Veterinary Medicine, 80, 33 40.
35. Roulet, A., Puel, O., Gesta, S., Lepage, J.F., Drag, M., Soll, M., Alvinerie, M. Pineau, T. (2003) MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. European Journal of Pharmacology, 460, 85 91.
36. Schinkel, A.H. (1997) The physiological function of drug-transporting P-glycoproteins. Seminars in Cancer Biology, 8, 161 170.
37. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P., Berns, A.J. Borst, P. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77, 491 502.
38. Schinkel, A.H., Wagenaar, E., Mol, C.A. van Deemter, L. (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. The Journal of Clinical Investigation, 97, 2517 2524.
39. Shoop, W.L., Mrozik, H. Fisher, M.H. (1995) Structure and activity of avermectins and milbemycins in animal health. Veterinary Parasitology, 59, 139 156.
40. 1a on chicken neuronal γ-aminobutyrate receptor channels expressed in Xenopus laevis oocytes. Molecular Pharmacology, 32, 749 752.
41. Soontornmalai, A., Vlaming, M.L. Fritschy, J.M. (2006) Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience, 138, 159 169.
42. Summerfield, S.G., Stevens, A.J., Cutler, L., del Carmen, O.M., Hammond, B., Tang, S.P., Hersey, A., Spalding, D.J. Jeffrey, P. (2006) Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. The Journal of Pharmacology and Experimental Therapeutics, 316, 1282 1290.
43. Tranquilli, W.J., Paul, A.J. Todd, K.S. (1991) Assessment of toxicosis induced by high-dose administration of milbemycin oxime in collies. American Journal of Veterinary Research, 52, 1170 1172.
44. Yas-Natan, E., Shamir, M., Kleinbart, S. Aroch, I. (2003) Doramectin toxicity in a collie. The Veterinary Record, 153, 718 720.